Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | EUR 52.85B | 1.42 | EUR 497.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 52.85B | 1.42 | EUR 495.60 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Regeneron Pharmaceuticals | Milan | Healthcare | Biotechnology & Medical Research | EUR 52.85B | 13.8x | 1.42 | EUR 498.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 44.20B | 58x | EUR 632.24 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | EUR 34.23B | 45.7x | 0.13 | EUR 560.60 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | EUR 34.23B | 45.7x | 0.13 | EUR 548.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 34.12B | 45.7x | 0.13 | EUR 551.20 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 34.06B | 45.7x | 0.13 | EUR 546.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | EUR 23.78B | 20.5x | 7.03 | EUR 132.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 21.92B | -31.2x | 0.19 | EUR 91.10 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | EUR 21.92B | -31.2x | 0.19 | EUR 92.80 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | EUR 21.92B | -31.2x | 0.19 | EUR 93.55 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 11.56B | 11.3x | 0.13 | EUR 183.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | EUR 11.54B | 11.3x | 0.13 | EUR 183.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 10.59B | 33.3x | 0.68 | EUR 53.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 10.59B | 33.3x | 0.68 | EUR 53.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Paris | Healthcare | Biotechnology & Medical Research | EUR 10.59B | 33.3x | 0.68 | EUR 54.88 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.7% Upside | Upgrade to Pro+ | |
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | EUR 10.59B | 33.3x | 0.68 | EUR 54.38 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 9.46B | -3.8x | -0.12 | EUR 24.06 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Xetra | Healthcare | Biotechnology & Medical Research | EUR 9.46B | -3.8x | -0.12 | EUR 24.45 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Milan | Healthcare | Biotechnology & Medical Research | EUR 9.46B | -3.8x | -0.12 | EUR 24.31 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | EUR 9.46B | -3.8x | -0.12 | EUR 24.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 9.34B | 21.5x | 0.11 | EUR 33.44 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 8.81B | -22.1x | -0.97 | EUR 145 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | EUR 8.16B | 110x | -1.44 | EUR 37.36 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | EUR 8.16B | 110x | -1.44 | EUR 37.41 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | EUR 8.16B | 110x | -1.44 | EUR 37.72 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 8.14B | 110x | -1.5 | EUR 37.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 8.14B | 110x | -1.44 | EUR 37.22 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 4.97B | -88x | -0.96 | EUR 77.06 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 4.17B | -10.6x | 0.56 | EUR 26.09 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 2.74B | -13.7x | 1.2 | EUR 32.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 2.11B | -6.4x | 0.04 | EUR 14.39 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 1.71B | -3.8x | 0.15 | EUR 30.90 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech AG BATS | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 1.71B | -3.8x | 0.15 | EUR 31.39 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | EUR 1.70B | -3.8x | 0.15 | EUR 31.20 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 1.55B | -8.6x | 0.05 | EUR 23.38 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | Amsterdam | Healthcare | Biotechnology & Medical Research | EUR 1.55B | -8.6x | 0.05 | EUR 23.52 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.6% Upside | Upgrade to Pro+ | |
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | EUR 1.55B | -8.6x | 0.05 | EUR 23.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 1.50B | -321.7x | 2.35 | EUR 22.34 | 19.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 1.47B | -321.7x | 2.34 | EUR 19.30 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | EUR 1.33B | -6.8x | 0.05 | EUR 7.45 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.4% Upside | Upgrade to Pro+ | |
Evotec AG | BATS Europe | Healthcare | Biotechnology & Medical Research | EUR 1.33B | -6.8x | 0.06 | EUR 7.03 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 1.33B | -6.8x | 0.05 | EUR 7.48 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49% Upside | Upgrade to Pro+ | |
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | EUR 1.33B | -6.8x | 0.05 | EUR 7.49 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | EUR 1.33B | -6.8x | 0.05 | EUR 7.51 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Syndax Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 1.04B | -3.9x | 0.14 | EUR 11.70 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Iovance Biotherapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 1.03B | -3.3x | -0.1 | EUR 3.13 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viridian Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 938.08M | -4.3x | -0.25 | EUR 11.35 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Frankfurt | Healthcare | Biotechnology & Medical Research | EUR 907.88M | -6.4x | -0.07 | EUR 5.66 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |